Briviact (in Italy: Nubriveo)

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
10-01-2024

Ingredient activ:

Brivaracetam

Disponibil de la:

UCB Pharma SA

Codul ATC:

N03AX23

INN (nume internaţional):

brivaracetam

Grupul Terapeutică:

Antiepileptics,

Zonă Terapeutică:

Epilepsy

Indicații terapeutice:

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

Rezumat produs:

Revision: 22

Statutul autorizaţiei:

Authorised

Data de autorizare:

2016-01-13

Prospect

                                99
B. PACKAGE LEAFLET
100
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BRIVIACT 10 MG FILM-COATED TABLETS
BRIVIACT 25 MG FILM-COATED TABLETS
BRIVIACT 50 MG FILM-COATED TABLETS
BRIVIACT 75 MG FILM-COATED TABLETS
BRIVIACT 100 MG FILM-COATED TABLETS
brivaracetam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Briviact is and what it is used for
2.
What you need to know before you take Briviact
3.
How to take Briviact
4.
Possible side effects
5.
How to store Briviact
6.
Contents of the pack and other information
1.
WHAT BRIVIACT IS AND WHAT IT IS USED FOR
WHAT BRIVIACT IS
Briviact contains the active substance brivaracetam. It belongs to a
group of medicines called
‘anti-epileptics’. These medicines are used to treat epilepsy.
WHAT BRIVIACT IS USED FOR
•
Briviact is used in adults, adolescents and children from 2 years of
age.
•
It is used to treat a type of epilepsy that has partial seizures with
or without a secondary
generalisation.
•
Partial seizures are fits that start by only affecting one side of the
brain. These partial seizures
can spread and extend to larger areas on both sides of the brain –
this is called a ‘secondary
generalisation’.
•
You have been given this medicine to lower the number of fits
(seizures) you have.
•
Briviact is used together with other medicines for epilepsy.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE BRIVIACT
DO NOT TAKE BRIVIACT IF:
-
you are allergic to brivaracetam, other similar chemical compounds as
levetiracetam or
piracetam or any of the oth
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Briviact 10 mg film-coated tablets
Briviact 25 mg film-coated tablets
Briviact 50 mg film-coated tablets
Briviact 75 mg film-coated tablets
Briviact 100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Briviact 10 mg film-coated tablets
Each film-coated tablet contains 10 mg brivaracetam.
Briviact 25 mg film-coated tablets
Each film-coated tablet contains 25 mg brivaracetam.
Briviact 50 mg film-coated tablets
Each film-coated tablet contains 50 mg brivaracetam.
Briviact 75 mg film-coated tablets
Each film-coated tablet contains 75 mg brivaracetam.
Briviact 100 mg film-coated tablets
Each film-coated tablet contains 100 mg brivaracetam.
Excipient(s) with known effect:
Briviact 10 mg film-coated tablets
Each 10 mg film-coated tablet contains 88 mg lactose.
Briviact 25 mg film-coated tablets
Each 25 mg film-coated tablet contains 94 mg lactose.
Briviact 50 mg film-coated tablets
Each 50 mg film-coated tablet contains 189 mg lactose.
Briviact 75 mg film-coated tablets
Each 75 mg film-coated tablet contains 283 mg lactose.
Briviact 100 mg film-coated tablets
Each 100 mg film-coated tablet contains 377 mg lactose.
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Briviact 10 mg film-coated tablets
White to off-white, round film-coated tablets of 6.5 mm in diameter
and debossed with ‘u10’ on one
side.
Briviact 25 mg film-coated tablets
Grey, oval film-coated tablets with dimensions of 8.9 mm x 5.0 mm and
debossed with ‘u25’ on one
side.
Briviact 50 mg film-coated tablets
Yellow, oval film-coated tablets with dimensions of 11.7 mm x 6.6 mm
and debossed with ‘u50’ on
one side.
Briviact 75 mg film-coated tablets
Purple, oval film-coated tablets with dimensions of 13.0 mm x 7.3 mm
debossed with ‘u75’ on one
side.
Briviact 100 mg film-coated tablets
Green-grey, oval film-coated tablets with dimensions of 14.5 mm x 8.1
mm and debossed with ‘u100’
on one side
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului bulgară 10-01-2024
Raport public de evaluare Raport public de evaluare bulgară 17-03-2022
Prospect Prospect spaniolă 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului spaniolă 10-01-2024
Raport public de evaluare Raport public de evaluare spaniolă 17-03-2022
Prospect Prospect cehă 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului cehă 10-01-2024
Raport public de evaluare Raport public de evaluare cehă 17-03-2022
Prospect Prospect daneză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului daneză 10-01-2024
Raport public de evaluare Raport public de evaluare daneză 17-03-2022
Prospect Prospect germană 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului germană 10-01-2024
Raport public de evaluare Raport public de evaluare germană 17-03-2022
Prospect Prospect estoniană 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului estoniană 10-01-2024
Raport public de evaluare Raport public de evaluare estoniană 17-03-2022
Prospect Prospect greacă 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului greacă 10-01-2024
Raport public de evaluare Raport public de evaluare greacă 17-03-2022
Prospect Prospect franceză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului franceză 10-01-2024
Raport public de evaluare Raport public de evaluare franceză 17-03-2022
Prospect Prospect italiană 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului italiană 10-01-2024
Raport public de evaluare Raport public de evaluare italiană 17-03-2022
Prospect Prospect letonă 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului letonă 10-01-2024
Raport public de evaluare Raport public de evaluare letonă 17-03-2022
Prospect Prospect lituaniană 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului lituaniană 10-01-2024
Raport public de evaluare Raport public de evaluare lituaniană 17-03-2022
Prospect Prospect maghiară 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului maghiară 10-01-2024
Raport public de evaluare Raport public de evaluare maghiară 17-03-2022
Prospect Prospect malteză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului malteză 10-01-2024
Raport public de evaluare Raport public de evaluare malteză 17-03-2022
Prospect Prospect olandeză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului olandeză 10-01-2024
Raport public de evaluare Raport public de evaluare olandeză 17-03-2022
Prospect Prospect poloneză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului poloneză 10-01-2024
Raport public de evaluare Raport public de evaluare poloneză 17-03-2022
Prospect Prospect portugheză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului portugheză 10-01-2024
Raport public de evaluare Raport public de evaluare portugheză 17-03-2022
Prospect Prospect română 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului română 10-01-2024
Raport public de evaluare Raport public de evaluare română 17-03-2022
Prospect Prospect slovacă 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului slovacă 10-01-2024
Raport public de evaluare Raport public de evaluare slovacă 17-03-2022
Prospect Prospect slovenă 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului slovenă 10-01-2024
Raport public de evaluare Raport public de evaluare slovenă 17-03-2022
Prospect Prospect finlandeză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului finlandeză 10-01-2024
Raport public de evaluare Raport public de evaluare finlandeză 17-03-2022
Prospect Prospect suedeză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului suedeză 10-01-2024
Raport public de evaluare Raport public de evaluare suedeză 17-03-2022
Prospect Prospect norvegiană 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului norvegiană 10-01-2024
Prospect Prospect islandeză 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului islandeză 10-01-2024
Prospect Prospect croată 10-01-2024
Caracteristicilor produsului Caracteristicilor produsului croată 10-01-2024
Raport public de evaluare Raport public de evaluare croată 17-03-2022

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor